InnerSpace Improves Cart Security and Efficiency with the InterConnect Lock System

InnerSpace, a Solaire Medical Company, today announced the launch of the InterConnect Lock system.

When connected to Wi-Fi and the InnerSpace Smart Solutions cloud-based platform, InterConnect Lock Plus allows administrators to manage the security of the cart fleet remotely from anywhere. The InterConnect Lock stores up to 9,800 individual users and administrator codes per fleet and features an OLED display screen.

The InterConnect Lock has an OLED screen and keypad designed for touch responsiveness, even when users are wearing gloves. The low-gloss, textured keypad is resistant to scratching and damage from cleaning.

“InterConnect provides healthcare administrators with more information and a more secure and efficient experience,” said Ben Barber, CEO, InnerSpace. “Paired with Smart Solutions, InterConnect Plus makes it easy to change security credentials and auto-lock times as well as identify who has access to each cart. Being able to manage credentials with the stroke of a key saves time and provides added security at the cart level.”

The Wi-Fi connected InterConnect Plus allows users to submit a request to team members to facilitate cart maintenance and restocking. Automatic alerts are provided for low battery and lost network connection. A downloadable report tracks cart access, alerts and users. In the event of a power outage, data is retained and automatically uploaded when power is restored.

“The need for this type of lock product has been around for a long time, but it’s been cost prohibitive,” Barber said. “In many cases, a WiFi-enabled lock could be double the cost of a cart. That upfront cost priced past solutions out of the market. Our cloud-based subscription service offers a more affordable option that also saves administrators time managing cart fleet security.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”